



Data Sheet

Research Use Only

Compound Name

Sorafenib

Catalog Number

SM95

Alternative Names

Bay 43-9006, Nexavar, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

Activity

Sorafenib is a multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit. It suppresses ERK phosphorylation. It also induces the phosphorylation of PKA.

Effect

Sorafenib has anti-tumor activity in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).

Purity

>99%

CAS

284461-73-0

Formula

$C_{21}H_{16}ClF_3N_4O_3$

Molecular Weight

464.82

Solubility

DMSO, ethanol

Stability

Stable at -20 °C. Keep away from direct sunlight.

References

1. Liu, L., et al. 2006. Cancer Res. 66(24): 11851-11858. PMID: 17178882
2. Aleman, JO., et al. 2014. Endocr Relat Cancer. 21(3): R247-259. PMID: 24478055
3. Wurth, R., et al. Biomed Res Int. 2014: 126586. PMID: 24527434